Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 9 ( September, 2022 ) > List of Articles


Is It Time to Revisit Remdesivir Use for Severe COVID-19?

Dipali Anand Taggarsi

Keywords : Cardiovascular complications, Coronavirus disease-2019, Coronavirus disease-2019 mortality, Major adverse cardiac event, Remdesivir

Citation Information : Taggarsi DA. Is It Time to Revisit Remdesivir Use for Severe COVID-19?. Indian J Crit Care Med 2022; 26 (9):983-984.

DOI: 10.5005/jp-journals-10071-24317

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


PDF Share
  1. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5):531–538. DOI: 10.1007/s00392-020-01626-9.
  2. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323(16):1574–1581. DOI: 10.1001/jama.2020.5394.
  3. Basu-Ray I, Almaddah Nk, Adeboye A, Soos MP. Cardiac Manifestations Of Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.
  4. Henein MY, Mandoli GE, Pastore MC, Ghionzoli N, Hasson F, Nisar MK, et al. Biomarkers predict in-hospital major adverse cardiac events in COVID-19 patients: A multicenter international study. JCM 2021;10(24):5863. DOI: 10.3390/jcm10245863.
  5. Roshdy A, Zaher S, Fayed H, Coghlan JG. COVID-19 and the heart: A systematic review of cardiac autopsies. Front Cardiovasc Med 2021;7:626975. DOI: 10.3389/fcvm.2020.626975.
  6. Almamlouk R, Kashour T, Obeidat S, Bois MC, Maleszewski JJ, Omrani OA, et al. COVID-19-associated cardiac pathology at the postmortem evaluation: A collaborative systematic review. Clin Microbiol Infect 2022;28(8):1066–1075. DOI: 10.1016/j.cmi.2022.03.021.
  7. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2022;399(10320):143–151. DOI: 10.1016/S0140-6736(21)01825-0.
  8. The REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021;385(9):777–789. DOI: 10.1056/NEJMoa2103417.
  9. Ma S, Xu C, Liu S, Sun X, Li R, Mao M, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Sig Transduct Target Ther 2021;6(1):83. DOI: 10.1038/s41392-021-00521-7.
  10. Pérez–Belmonte LM, Sanz–Cánovas J, Salinas A, Fornie IS, Méndez–Bailón M, Gómez-Huelgas R, et al. Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: A multicenter retrospective study. Intern Emerg Med 2021;16(8):2301–2305. DOI: 10.1007/s11739-021-02843-4.
  11. Kamarullah W, Nurcahyani, Josephine CM, Multazam RB, Nawing AG, Dharma S. Corticosteroid therapy in management of myocarditis associated with COVID-19: A systematic review of current evidence. Arch Acad Emerg Med 2021;9(1):e32. DOI: 10.22037/aaem.v9i1.1153.
  12. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19: Final report. N Engl J Med 2020;383(19):1813–1826. DOI: 10.1056/NEJMoa2007764.
  13. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao–Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19: Interim WHO Solidarity trial results. N Engl J Med 2021;384(6):497–511. DOI: 10.1056/NEJMoa2023184.
  14. Tanni ES, Silvinato A, Floriano I, Bacha HA, Barbosa AN, Bernado WM. Use of remdesivir in patients with COVID-19: A systematic review and meta-analysis. J Bras Pneumol 2022;48(1):e20210393. DOI: 10.36416/1806-3756/e20210393.
  15. Panda R, Singh P, Jain G, Saigal S, Karna ST, Anand A, et al. Effect of remdesivir administration on occurrence of major adverse cardiac events in critically ill COVID-19 pneumonia: A retrospective observational study. Indian J Crit Care Med 2022;26(9):993–999.
  16. Bose D, Gogtay N, Rajan S. Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. Lung India 2021;38(4): 382–386. DOI: 10.4103/lungindia.lungindia_883_20.
  17. Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis 2021;106:71–77. DOI: 10.1016/j.ijid.2021.02.092.
  18. Marpakwar C. Amid a massive shortage of Remdesivir, politicians step in to hand out lifesaving COVID-19 drug to desperate families. 2022. Available at: Accessed on:14 August 2022.
  19. Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, Solmi M, et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical Transl Sci 2022;15(2):501–513. DOI: 10.1111/cts.13168.
  20. Nabati M, Parsaee H. Potential cardiotoxic effects of Remdesivir on cardiovascular system: A literature review. Cardiovasc Toxicol 2022;22(3):268–272. DOI: 10.1007/s12012-021-09703-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.